List of Excipients in Branded Drug FESOTERODINE FUMARATE

Generic Drugs Containing FESOTERODINE FUMARATE

Company	Ingredient	NDC	Excipient
Camber Pharmaceuticals Inc	fesoterodine fumarate	31722-033	CITRIC ACID MONOHYDRATE
Camber Pharmaceuticals Inc	fesoterodine fumarate	31722-033	FD&C BLUE NO. 2
Camber Pharmaceuticals Inc	fesoterodine fumarate	31722-033	GLYCERYL DIBEHENATE
Camber Pharmaceuticals Inc	fesoterodine fumarate	31722-033	HYPROMELLOSE 2208
Camber Pharmaceuticals Inc	fesoterodine fumarate	31722-033	LECITHIN, SOYBEAN
Camber Pharmaceuticals Inc	fesoterodine fumarate	31722-033	POLYETHYLENE GLYCOL 3350
Camber Pharmaceuticals Inc	fesoterodine fumarate	31722-033	POLYVINYL ALCOHOL

What are the Most Frequently-Used Excipients in FESOTERODINE FUMARATE?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
7	CELLULOSE, MICROCRYSTALLINE
4	CITRIC ACID MONOHYDRATE
13	FD&C BLUE NO. 2
1	FERRIC OXIDE RED
3	FERRIC OXIDE YELLOW
1	FERROSOFERRIC OXIDE

Last updated: August 10, 2026

ecutive summary: Fesoterodine fumarate is an extended-release antimuscarinic marketed as Toviaz for overactive bladder. The commercial opportunity is primarily in generic and differentiated extended-release tablets, with excipient selection focused on reproducible release, low moisture sensitivity, tablet robustness, color differentiation, and efficient scale-up. The core formulation is relatively conventional, which limits broad composition-of-matter opportunities but leaves room for formulation optimization, regional generic supply, alternative manufacturing processes, and patient-focused dosage forms.

Fesoterodine Fumarate Excipient Strategy and Commercial Opportunities

What is fesoterodine fumarate and how is it formulated?

Fesoterodine fumarate is an orally administered prodrug that is rapidly converted to the active metabolite 5-hydroxymethyl tolterodine, also known as 5-HMT. It is a competitive muscarinic receptor antagonist used to treat urinary urgency, increased urinary frequency, and urge urinary incontinence associated with overactive bladder.

Toviaz is supplied as once-daily extended-release tablets in 4 mg and 8 mg strengths. The product uses a solid oral matrix formulation rather than an osmotic pump or multiparticulate capsule. The dosage form is designed to provide controlled release over the dosing interval and reduce peak-related tolerability problems associated with immediate-release antimuscarinic therapy. [1]

Reference formulation and excipient functions

The U.S. labeling identifies the following principal inactive ingredients:

Formulation component	Reported excipient or material	Primary function
Diluent	Lactose monohydrate	Adds bulk and supports tablet compression
Filler and compression aid	Microcrystalline cellulose	Improves compactibility and tablet strength
Binder	Hydroxypropyl cellulose	Supports granule and tablet cohesion
Disintegrant or pore-forming component	Sodium starch glycolate	Promotes fluid ingress and matrix erosion
Lubricant	Magnesium stearate	Reduces sticking and ejection force
Film former	Hypromellose	Provides tablet coating and surface protection
Plasticizer	Triacetin	Improves coating flexibility
Opacifier and colorant	Titanium dioxide and colorants	Provides appearance, light protection, and strength differentiation
Anti-tacking agent	Talc	Improves coating performance

The exact excipient grade, particle-size distribution, moisture content, substitution level, and manufacturing sequence can materially affect dissolution. A generic applicant cannot assume that matching the qualitative ingredient list will produce equivalent release.

Which excipients control fesoterodine fumarate extended release?

The most important technical issue is the release mechanism. Fesoterodine fumarate tablets contain a relatively low drug load compared with the total tablet mass, so excipients determine tablet porosity, water penetration, mechanical strength, and release reproducibility.

Matrix-forming and release-controlling strategy

A practical development strategy should evaluate:

1. Hydrophilic polymer level and grade.
2. Tablet porosity after compression.
3. Disintegrant concentration and distribution.
4. Lubrication time and magnesium stearate coverage.
5. Granulation endpoint and residual moisture.
6. Coating weight gain and film permeability.
7. Dissolution behavior across pH, agitation, and mechanical stress.

Hydroxypropyl cellulose can act as a binder and influence matrix hydration. Microcrystalline cellulose affects compact density and capillary water uptake. Sodium starch glycolate can accelerate wetting and tablet breakup. These excipients can create a narrow formulation design space if the product relies on controlled erosion rather than a single high-viscosity polymer barrier.

The commercial target is not simply a nominal dissolution profile. The formulation must maintain release similarity across manufacturing sites, equipment scales, raw-material suppliers, and normal process variation.

Salt handling and moisture control

Fesoterodine fumarate is a salt form with potential sensitivity to humidity, particle-size variation, and electrostatic handling. Development teams should characterize:

• Water activity and equilibrium moisture.
• Hygroscopicity of the active pharmaceutical ingredient.
• Solid-state form and crystallinity.
• API-excipient compatibility.
• Conversion or degradation under accelerated storage.
• Blend segregation at low drug load.
• Lubricant sensitivity during compression.

Moisture management is commercially important because the product is a film-coated tablet, and the coating process, packaging system, and storage conditions may influence dissolution over shelf life. High-barrier blister packaging can reduce moisture exposure but may increase packaging cost. Bottles with desiccants can lower unit cost while adding component and packaging validation requirements.

What formulation patents protect fesoterodine fumarate products?

The principal commercial protection for fesoterodine fumarate has historically centered on the active compound, prodrug chemistry, pharmaceutical compositions, and extended-release dosage forms. Product protection for Toviaz has also involved regulatory exclusivity and Orange Book-listed patents associated with the approved drug product. The relevant patent position should be confirmed against the current FDA Orange Book and jurisdiction-specific registers before filing, licensing, or launch planning. [2]

Composition-of-matter protection

Composition-of-matter rights generally provide the strongest protection because they cover the active molecule or salt independent of a particular excipient system. For fesoterodine, the commercial significance of those rights has declined following expiration of the primary product protection and the emergence of generic extended-release products in major markets.

A later entrant may still face risk from:

• Salt or polymorph claims.
• Specific stereochemical forms.
• Controlled-release composition claims.
• Manufacturing process claims.
• Dosage regimen claims.
• Combination-product claims.
• Patent claims covering a specific dissolution profile.

A formulation that uses a different excipient system does not automatically avoid infringement. Patent scope depends on the claim language, including whether claims require named excipients, quantitative ranges, functional release characteristics, or process steps.

Formulation and manufacturing claims

The strongest residual formulation opportunities usually arise from narrow technical claims, such as:

• A defined polymer-to-drug ratio.
• A tablet with specified dissolution at multiple time points.
• A granulation process producing a target porosity.
• A coating system that controls moisture ingress.
• A low-force compression process that improves content uniformity.
• A formulation that reduces food-effect variability.
• A manufacturing method that improves impurity control.

Such claims may protect a commercial design but usually do not create the same barrier as composition-of-matter rights. Their value depends on whether competing manufacturers can reach bioequivalence through a different formulation pathway.

When did fesoterodine fumarate lose major exclusivity protection?

Fesoterodine fumarate was developed by Schwarz Pharma and commercialized by Pfizer under the Toviaz brand. The product received U.S. FDA approval in 2008. [1,3]

The primary commercial exclusivity period has passed in the United States and other major markets. Generic entry has occurred or been authorized in several jurisdictions, although approval timing, patent certification, and launch rights differ by country.

Milestone	Commercial significance
U.S. approval of Toviaz	Established the reference product and FDA safety and efficacy standard
Marketed strengths	4 mg and 8 mg extended-release tablets
Primary protection period	Historically delayed broad generic competition
Post-exclusivity period	Shifted value toward manufacturing cost, supply reliability, and bioequivalence
Current market structure	Branded product, authorized or conventional generics, and regional suppliers

The exact launch date for a particular generic depends on the applicant, patent certifications, settlement terms, tentative or final approval, and local regulatory status. The Orange Book remains the controlling source for current U.S. listed patents and exclusivity information. [2]

What is the FDA regulatory status of fesoterodine fumarate?

Toviaz is an FDA-approved prescription extended-release tablet. The U.S. product is approved in 4 mg and 8 mg strengths for adults with overactive bladder. The label recommends a starting dose of 4 mg once daily, with an increase to 8 mg based on individual response and tolerability. [1]

Generic applicants generally pursue an abbreviated new drug application under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The key technical requirements include:

• Same active ingredient and dosage form.
• Same route of administration.
• Pharmaceutical equivalence.
• Demonstrated bioequivalence.
• Acceptable stability and manufacturing controls.
• Compliance with current good manufacturing practice.
• Labeling consistent with the reference product, subject to permitted differences.

For an extended-release product, the critical regulatory risk is failure to match the reference product’s pharmacokinetic and dissolution behavior. A formulation can show acceptable in vitro release under one condition yet fail under fed, fasting, high-fat meal, alcohol-interaction, or dose-strength conditions.

How should a generic company design the excipient platform?

A generic applicant has three main formulation paths.

Path one: reference-like composition

The lowest development risk is to use excipients that are qualitatively and quantitatively similar to the reference product. This approach can simplify formulation development and reduce the number of variables during bioequivalence work.

Its disadvantages are dependence on particular grades, potential difficulty sourcing equivalent materials, and limited differentiation from other generic applicants.

Path two: equivalent-function formulation

A company can replace individual excipients with materials that provide the same functional role. Examples include:

• Lactose replacement with dibasic calcium phosphate or mannitol.
• Hydroxypropyl cellulose replacement with povidone or another suitable binder.
• Alternative disintegrant systems.
• Alternative film-former and plasticizer combinations.
• Reduced or eliminated titanium dioxide where local regulation or customer preference supports it.

This path may reduce cost or improve supply resilience. It requires stronger comparative dissolution and bioequivalence control because changes in density, porosity, wettability, and coating permeability can shift release.

Path three: differentiated controlled-release platform

A company may use a proprietary matrix, coated particles, mini-tablets, or a multiparticulate system. This can support a lifecycle product with improved manufacturing robustness, a lower food effect, or a more consistent release profile.

The disadvantages are higher development expense, greater regulatory complexity, possible device or manufacturing claims, and the risk that the differentiated system does not produce a commercially meaningful clinical advantage.

What commercial opportunities exist in fesoterodine fumarate excipients?

The strongest opportunities are in formulation supply, contract development, generic manufacturing, and lifecycle products rather than new-drug discovery.

Excipient supply opportunities

Suppliers can target:

• Direct-compression lactose and microcrystalline cellulose grades.
• Low-moisture excipients for humidity-sensitive formulations.
• High-functionality cellulose products.
• Co-processed excipients for improved flow and content uniformity.
• Low-titanium-dioxide coating systems.
• Film coatings optimized for controlled-release tablets.
• Magnesium stearate grades with controlled surface area and fatty-acid composition.
• Packaging systems with moisture-barrier performance.

The active dose is small enough that blend uniformity and segregation control can create value. Excipient suppliers that provide formulation support, compaction data, and scale-up protocols have a stronger commercial position than commodity suppliers selling only raw material.

Generic manufacturing opportunities

Fesoterodine is suitable for manufacturers with:

• Extended-release tablet technology.
• High-containment or low-dose blending capabilities.
• Robust dissolution testing.
• Access to regulated-market excipients.
• Reliable supply of pharmaceutical-grade API.
• Experience with ANDA or equivalent generic submissions.

Contract manufacturers may offer development and commercial production for regional licensees that lack controlled-release manufacturing infrastructure.

Lifecycle management opportunities

Potential differentiated products include:

• Lower-cost generic extended-release tablets.
• Smaller or easier-to-swallow tablets.
• Alternative packaging for adherence and moisture protection.
• Modified-color or colorant-free tablets.
• Fixed-dose combinations, where clinically and regulatorily justified.
• Formulations optimized for patients with swallowing difficulty.
• Regional products using excipients accepted by local pharmacopoeias.

A new dosage form must address a defined patient or economic need. A simple excipient substitution is unlikely to support premium pricing unless it improves manufacturability, stability, tolerability, or access.

How does fesoterodine compare with competing overactive-bladder drugs?

Fesoterodine competes with tolterodine, oxybutynin, solifenacin, darifenacin, trospium, and beta-3 agonists such as mirabegron and vibegron. Antimuscarinic products compete on efficacy, dry-mouth and constipation rates, cognitive tolerability, dosing convenience, generic price, and prescriber familiarity.

Product class	Typical commercial advantage	Excipient opportunity
Fesoterodine ER	Once-daily dosing and established antimuscarinic efficacy	Generic ER tablet and supply-cost optimization
Tolterodine ER	Mature generic market	High-volume low-cost manufacturing
Solifenacin	Strong brand recognition and once-daily use	Tablet robustness and regional generic supply
Oxybutynin ER	Broad historical use	Alternative release systems and low-cost production
Mirabegron	Non-antimuscarinic mechanism	Less direct excipient competition, stronger differentiation pressure
Vibegron	Newer beta-3 agonist positioning	Premium product and lifecycle formulation opportunities

Fesoterodine’s commercial weakness is class competition from generic antimuscarinics and beta-3 agonists. Its opportunity is a controlled-release product with reliable quality and a lower cost structure.

Which companies are challenging or supplying fesoterodine generics?

Generic availability varies by jurisdiction and time. U.S. supplier status should be checked through FDA-approved drug databases, the Orange Book, and current application records. European and other national markets may include manufacturers that do not market in the United States.

The competitive field generally includes:

• Large multinational generic companies.
• Regional European generic manufacturers.
• Contract development and manufacturing organizations.
• Specialty suppliers using differentiated extended-release technology.

Supplier selection should weigh approval status, current commercial availability, API sourcing, manufacturing site history, shortage exposure, and ability to maintain both 4 mg and 8 mg strengths.

What patent litigation and settlement issues affect launch timing?

Patent disputes for generic fesoterodine typically arise through Paragraph IV certifications or equivalent national procedures. The main launch variables are:

• Whether an Orange Book patent remains listed.
• Whether the generic applicant certifies invalidity, unenforceability, or non-infringement.
• Whether the patent holder files an infringement action within the statutory period.
• Whether a 30-month stay applies.
• Whether the parties reach a settlement.
• Whether an authorized generic is launched.
• Whether the applicant receives first-filer status.

A settlement may provide a defined entry date, but its commercial value depends on the agreed launch date, supply restrictions, authorized-generic terms, and the scope of covered formulations. Patent litigation cannot be assessed from the excipient list alone. Claim construction and infringement analysis are required for any specific formulation.

What generic launch risks exist for fesoterodine fumarate?

The principal risks are technical and commercial rather than purely patent-based.

Risk	Business effect	Mitigation
Dissolution mismatch	Bioequivalence failure or post-approval variability	Develop discriminatory dissolution methods
API particle-size variability	Blend and release inconsistency	Tight API specifications and process controls
Excipient grade change	Unexpected release shift	Supplier qualification and comparability testing
Moisture uptake	Stability or dissolution failure	High-barrier packaging and humidity controls
Low-dose segregation	Content-uniformity failures	Controlled blending and material engineering
Market price erosion	Lower return on development investment	Multi-market filing and efficient scale-up
Limited demand	Excess inventory and weak capacity utilization	Dual-strength production planning
Class competition	Reduced prescribing and reimbursement	Low-cost supply and differentiated adherence value

How strong is the fesoterodine fumarate patent estate?

The estate is commercially weaker than during the branded exclusivity period because the core product has been on the market for many years and generic competition has developed. Residual strength may remain in narrow formulation, process, or method-of-use claims, but the practical barrier depends on claim breadth and the number of non-infringing formulation routes.

For a generic company, the estate should be scored across five dimensions:

1. Remaining enforceable patent term.
2. Claim coverage of the intended tablet architecture.
3. Availability of alternative excipient systems.
4. Likelihood of a successful Paragraph IV challenge.
5. Expected price erosion after entry.

For an excipient supplier, narrow formulation claims can still create licensing opportunities if the supplier’s material is necessary to achieve the claimed release profile. The supplier should avoid relying on generic functional descriptions and instead document grade-specific performance and freedom-to-operate positions.

Key takeaways

• Fesoterodine fumarate is a mature extended-release tablet opportunity.
• The reference formulation uses conventional excipients, including lactose, microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate, magnesium stearate, and a film-coating system.
• Release performance depends on excipient grade, moisture, porosity, lubrication, granulation, and coating controls.
• Generic opportunities are strongest in regulated-market supply, cost-efficient manufacturing, and regional distribution.
• Excipient substitution is feasible but requires rigorous dissolution and bioequivalence development.
• Narrow formulation and manufacturing patents may remain relevant even after major product exclusivity has expired.
• Competitive pressure comes from generic antimuscarinics and beta-3 agonists, especially mirabegron and vibegron.
• Commercial value is driven by reliable supply, low manufacturing cost, dual-strength availability, and regulatory execution.

FAQs

Is fesoterodine fumarate an immediate-release or extended-release drug?

It is marketed primarily as a once-daily extended-release tablet in 4 mg and 8 mg strengths.

Can lactose be removed from a fesoterodine fumarate generic?

Yes, a lactose-free formulation may be technically feasible, but the replacement must preserve tablet strength, release behavior, stability, and bioequivalence.

Which excipient is most important for fesoterodine extended release?

No single excipient controls the product alone. The combined effects of binder, filler, disintegrant, tablet porosity, lubrication, and coating permeability determine release.

Is there an opportunity for a fesoterodine fumarate orally disintegrating tablet?

There may be a lifecycle opportunity, but an orally disintegrating dosage form must address the challenge of maintaining controlled release while achieving rapid oral dispersion.

Are biosimilar risks relevant to fesoterodine fumarate?

No. Fesoterodine fumarate is a chemically synthesized small molecule, so competition proceeds through generic-drug pathways rather than biosimilar regulation.

References

1. U.S. Food and Drug Administration. (2008). Toviaz (fesoterodine fumarate) extended-release tablets: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. European Medicines Agency. (2007). Toviaz: EPAR and product information.
4. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms and extended-release products: Regulatory guidance.
5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.-end-